Publications

Ramnarine VRohan, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M et al..  2018.  The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.. Gigascience.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, G Han C, Coleman I et al..  2018.  The long tail of oncogenic drivers in prostate cancer.. Nat Genet. 50(5):645-651.

Terry S, Beltran H.  2014.  The many faces of neuroendocrine differentiation in prostate cancer progression.. Front Oncol. 4:60.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KMun, Angeles A, Johnson F et al..  2017.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.. Cancer Discov. 7(1):54-71.

Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discovery. 1(6):487-95.

Puca L, Vlachostergios PJ, Beltran H.  2018.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.. Cold Spring Harb Perspect Med.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST et al..  2011.  New therapies for castration-resistant prostate cancer: efficacy and safety.. Eur Urol. 60(2):279-90.

Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH et al..  2012.  Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.. Mol Cancer Ther. 11(3):775-83.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.  2012.  Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).. BJU Int. 109(7):968-85.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.

Sailer V, Pauli C, Merzier EC, Mosquera JMiguel, Beltran H, Rubin MA, Rao RA.  2017.  On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.. Anticancer Res. 37(4):1569-1573.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK et al..  2014.  Organoid cultures derived from patients with advanced prostate cancer.. Cell. 159(1):176-87.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.. Cancer Discov.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2018.  A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.. Clin Cancer Res.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.

Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera J-M, Reuter VE, Robinson BD, Troncoso P, Rubin MA.  2014.  Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.. Am J Surg Pathol. 38(6):756-67.

Sternberg CN, Beltran H.  2017.  Prostate cancer in 2016: Improved outcomes and precision medicine come within reach.. Nat Rev Urol. 14(2):71-72.

Beltran H, Demichelis F.  2015.  Prostate cancer: Intrapatient heterogeneity in prostate cancer.. Nat Rev Urol. 12(8):430-1.

Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM et al..  2014.  Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.. Hum Pathol. 45(10):2136-43.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.

Klimstra DS, Beltran H, Lilenbaum R, Bergsland E.  2015.  The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.. Am Soc Clin Oncol Educ Book. :92-103.

Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang Y et al..  2017.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.. Eur Urol. 71(1):68-78.